Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Abstract Background Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking. Methods A retrospective analysis of patients (pts) with metastatic clear cell renal...

Full description

Bibliographic Details
Main Authors: Haris Zahoor, Pedro C. Barata, Xuefei Jia, Allison Martin, Kimberly D. Allman, Laura S. Wood, Timothy D. Gilligan, Petros Grivas, Moshe C. Ornstein, Jorge A. Garcia, Brian I. Rini
Format: Article
Language:English
Published: BMJ Publishing Group 2018-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Renal cell carcinoma
Clear cell
Immunotherapy
Nivolumab
Biomarker
Failure
Online Access:http://link.springer.com/article/10.1186/s40425-018-0425-8

Internet

http://link.springer.com/article/10.1186/s40425-018-0425-8

Similar Items